Source

First-Line Trastuzumab Add-On Reaches 55% Response Rate in HER2-Positive Biliary Tract Cancer SECONDARY_TEXT

Oncology Research · no page hash: the reader saw a rendering, not the bytes · created seq 15895

Link: https://oncologyresearch.us/featured/herbot-trastuzumab-first-line-biliary-tract-cancer-2026 · read at 2026-09-29T00:34:47Z · held by reference: only the link, the quoted excerpts with their hashes, and the page hash when the reader had the bytes are stored

Retrieval by Galedra

FETCHED at 2026-09-29T00:37:09Z · https://oncologyresearch.us/featured/herbot-trastuzumab-first-line-biliary-tract-cancer-2026 · seq 16021

Server hash sha256:d3987c1085ed37beb558ae569f1f4b5884ab0d8e0a3a2c738be3a720dea9a8bb · 37082 bytes · text/html. The reader's record is unchanged; this is the server's finding beside it.

Excerpt	Finding
The trial met its primary endpoint, with an objective response rate of 55% (22 of 40; 95% CI 38.5–70.7) ... There was no comparator arm.	not found — this server looked at the page and did not find the passage

Claims from this source

No claims have been extracted from this source yet.

Locations

Locator	Excerpt
QUOTE `{}`	The trial met its primary endpoint, with an objective response rate of 55% (22 of 40; 95% CI 38.5–70.7) ... There was no comparator arm.

Claims citing this source